For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.

Obesity is an epidemic that affects more than 40% of all American adults, and it's creating a feeding frenzy for investors.

With the rise of obesity-fighting medications from pharmaceutical companies Eli Lilly and Novo Nordisk, the weight loss drug market could be worth $100 billion in the next few years. Naturally, other companies want in and investors are pivoting away from healthcare stocks that can't match that growth potential.

Continue reading

Source Fool.com